Ratings by JPMorgan (Brian Cheng)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/24/2026 | Shattuck Labs | STTK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2026 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
28.36 (26.63) |
-6.1% | Details | |
| 6/2/2026 | Odyssey Therapeutics | ODTX | New Coverage | Overweight (N/A) |
17.01 (18.66) |
9.7% | Details | |
| 5/14/2026 | Protara Therapeutics | TARA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2026 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/11/2026 | Xencor, Inc. | XNCR | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/11/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/11/2026 | CG Oncology | CGON | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/1/2026 | Arrowhead Pharma | ARWR | New Coverage | Overweight (N/A) |
70.53 (85.60) |
21.37% | Details | |
| 4/17/2026 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/16/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/16/2026 | Allogene | ALLO | Upgrade | Neutral (Underweight) |
2.17 (1.74) |
-19.82% | Details | |
| 3/24/2026 | Xencor, Inc. | XNCR | Downgrade | Neutral (Overweight) |
12.05 (19.44) |
61.33% | Details | |
| 3/4/2026 | Protara Therapeutics | TARA | New Coverage | Overweight (N/A) |
5.97 (4.02) |
-32.66% | Details | |
| 3/4/2026 | Protara Therapeutics | TARA | New Coverage | Overweight (N/A) |
5.97 (5.97) |
0% | Details | |
| 3/2/2026 | Revolution | RVMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Overweight (N/A) |
13.64 (8.90) |
-34.75% | Details | |
| 2/27/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/9/2026 | Immunovant | IMVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/2/2026 | TG Therapeutics | TGTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/2/2026 | Revolution | RVMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2026 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2026 | Immunome Inc. | IMNM | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2025 | Opko Health | OPK | New Coverage | Neutral (N/A) |
1.28 (1.22) |
-4.69% | Details | |
| 11/19/2025 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/19/2025 | Immunovant | IMVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/7/2025 | Intellia Therapeutics | NTLA | Downgrade | Underweight (Neutral) |
13.57 (10.73) |
-20.93% | Details | |
| 11/6/2025 | Xencor, Inc. | XNCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/10/2025 | Pliant Therapeutics | PLRX | Downgrade | Underweight (Neutral) |
1.53 (1.09) |
-28.76% | Details | |
| 10/10/2025 | Allogene | ALLO | Downgrade | Underweight (Neutral) |
1.47 (2.17) |
47.62% | Details | |
| 10/2/2025 | Absci Corp. | ABSI | New Coverage | Overweight (N/A) |
3.04 (7.56) |
148.68% | Details | |
| 10/1/2025 | Zymeworks | ZYME | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/1/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/30/2025 | Immunovant | IMVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/18/2025 | Roivant Sciences | ROIV | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/18/2025 | CRISPR Therapeutics | CRSP | New Coverage | Overweight (N/A) |
61.19 (46.54) |
-23.94% | Details | |
| 8/15/2025 | Precigen Inc. | PGEN | Upgrade | Neutral (Underweight) |
1.91 (5.40) |
182.72% | Details | |
| 8/12/2025 | Immunovant | IMVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2025 | Immunome Inc. | IMNM | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/1/2025 | Allogene | ALLO | Downgrade | Neutral (Overweight) |
1.23 (1.47) |
19.51% | Details | |
| 6/2/2025 | Blueprint Medicines | BPMC | Downgrade | Neutral (Overweight) |
101.35 (129.46) |
27.74% | Details | |
| 6/2/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2025 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2025 | Blueprint Medicines | BPMC | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
26.94 (69.32) |
157.31% | Details | |
| 3/27/2025 | Ascentage Pharma Group | AAPG | New Coverage | Overweight (N/A) |
18.46 (18.29) |
-0.92% | Details | |
| 3/3/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Xencor, Inc. | XNCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Intellia Therapeutics | NTLA | Downgrade | Neutral (Overweight) |
10.80 (13.57) |
25.65% | Details | |
| 2/4/2025 | Protagonist Therapeutics | PTGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/4/2025 | Blueprint Medicines | BPMC | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/30/2025 | Cargo Therapeutics | CRGX | Downgrade | Underweight (Neutral) |
13.19 (4.47) |
-66.11% | Details | |
| 12/16/2024 | Zymeworks | ZYME | Upgrade | Overweight (Neutral) |
12.62 (22.86) |
81.14% | Details | |
| 12/16/2024 | Editas Medicine | EDIT | Downgrade | Underweight (Neutral) |
1.89 (2.60) |
37.57% | Details | |
| 11/14/2024 | Blueprint Medicines | BPMC | New Coverage | Overweight (N/A) |
96.62 (101.35) |
4.9% | Details | |
| 11/8/2024 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2024 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2024 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2024 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2024 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2024 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2024 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/11/2024 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2024 | Metagenomi Inc | MGX | Downgrade | Neutral (Overweight) |
7.02 (1.21) |
-82.76% | Details | |
| 4/30/2024 | Immunome Inc. | IMNM | New Coverage | Overweight (N/A) |
13.73 (22.21) |
61.76% | Details | |
| 4/2/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2024 | Precigen Inc. | PGEN | Downgrade | Underweight (Neutral) |
1.44 (5.40) |
275% | Details | |
| 3/19/2024 | Mersana | MRSN | Upgrade | Neutral (Underweight) |
5.04 (29.08) |
476.98% | Details | |
| 3/12/2024 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 3/5/2024 | Metagenomi Inc | MGX | New Coverage | Overweight (N/A) |
12.00 (1.21) |
-89.92% | Details | |
| 3/4/2024 | Kyverna Therapeutics Inc | KYTX | New Coverage | Overweight (N/A) |
27.17 (7.41) |
-72.73% | Details | |
| 2/28/2024 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2024 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2024 | Editas Medicine | EDIT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/20/2024 | Immunovant | IMVT | New Coverage | Overweight (N/A) |
37.80 (39.41) |
4.26% | Details | |
| 1/30/2024 | Cargo Therapeutics | CRGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/5/2023 | Cargo Therapeutics | CRGX | New Coverage | Overweight (N/A) |
16.29 (13.19) |
-19.03% | Details | |
| 11/10/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2023 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 10/18/2023 | Editas Medicine | EDIT | Upgrade | Neutral (Underweight) |
6.81 (2.60) |
-61.82% | Details | |
| 10/2/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/2/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | ADC Therapeutics | ADCT | Upgrade | Neutral (Underweight) |
1.50 (1.15) |
-23.33% | Details | |
| 8/2/2023 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/27/2023 | Mersana | MRSN | Downgrade | Underweight (Neutral) |
3.91 (29.08) |
643.73% | Details | |
| 6/16/2023 | Mersana | MRSN | Downgrade | Neutral (Overweight) |
9.55 (29.08) |
204.5% | Details | |
| 6/1/2023 | Adicet Bio Inc. | ACET | Downgrade | Neutral (Overweight) |
5.48 (7.79) |
42.15% | Details | |
| 5/23/2023 | Precigen Inc. | PGEN | New Coverage | Neutral (N/A) |
1.29 (5.40) |
318.6% | Details | |
| 5/9/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2023 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2023 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2023 | Adicet Bio Inc. | ACET | Maintain | (Overweight) |
|
Details | ||
| 3/16/2023 | Mersana | MRSN | Upgrade | Overweight (Neutral) |
4.55 (9.55) |
109.89% | Details | |
| 3/7/2023 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2023 | Allogene | ALLO | Upgrade | Overweight (Neutral) |
6.55 (1.74) |
-73.44% | Details | |
| 12/16/2022 | Senti Biosciences, Inc. | SNTI | New Coverage | Neutral (N/A) |
1.52 (0.40) |
-73.68% | Details | |
| 12/7/2022 | Gossamer Bio Inc. | GOSS | Downgrade | Underweight (Neutral) |
9.29 (0.14) |
-98.49% | Details | |
| 11/10/2022 | Clovis Oncology | CLVS | Downgrade | Underweight (Neutral) |
0.98 (0.08) |
-91.84% | Details | |
| 10/28/2022 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 9/21/2022 | Gossamer Bio Inc. | GOSS | New Coverage | Neutral (N/A) |
13.60 (0.14) |
-98.97% | Details | |
| 9/21/2022 | Xencor, Inc. | XNCR | New Coverage | Overweight (N/A) |
27.61 (12.05) |
-56.36% | Details | |
| 9/21/2022 | Intellia Therapeutics | NTLA | New Coverage | Overweight (N/A) |
62.53 (10.80) |
-82.73% | Details | |
| 9/21/2022 | ADC Therapeutics | ADCT | New Coverage | Overweight (N/A) |
5.29 (1.15) |
-78.26% | Details | |
| 9/21/2022 | Adicet Bio Inc. | ACET | New Coverage | Overweight (N/A) |
14.81 (7.79) |
-47.4% | Details | |
| 8/2/2022 | Zymeworks | ZYME | New Coverage | Neutral (N/A) |
5.84 (22.86) |
291.44% | Details | |
| 8/2/2022 | Protagonist Therapeutics | PTGX | New Coverage | Overweight (N/A) |
9.95 (136.11) |
1267.94% | Details | |
| 8/2/2022 | Mersana | MRSN | New Coverage | Neutral (N/A) |
5.07 (29.08) |
473.57% | Details | |
| 8/2/2022 | Editas Medicine | EDIT | New Coverage | Underweight (N/A) |
15.91 (6.81) |
-57.2% | Details | |
| 8/2/2022 | Clovis Oncology | CLVS | New Coverage | Neutral (N/A) |
1.67 (0.08) |
-95.21% | Details | |
| 8/2/2022 | BioAtla Inc. | BCAB | New Coverage | Overweight (N/A) |
3.40 (3.37) |
-0.88% | Details | |
| 8/2/2022 | Allogene | ALLO | New Coverage | Neutral (N/A) |
12.98 (1.74) |
-86.59% | Details |
